SQURPHARMA 21-Jan-2020 Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
SQURPHARMA 21-Jan-2020 Mr. Anjan Chowdhury, one of the Directors of the Company, has expressed his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
SQURPHARMA 21-Jan-2020 The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2019 to the respective shareholders.
SQURPHARMA 16-Jan-2020 Tapan Chowdhury, one of the Directors of the Company, has expressed his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
SQURPHARMA 16-Jan-2020 Samuel S Chowdhury, one of the Directors of the Company, has expressed his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
SQURPHARMA 23-Dec-2019 Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2019; unaudited financials up to September 30, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
SQURPHARMA 17-Dec-2019 The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2019 to the respective shareholders' BO Accounts on December 17, 2019.
SQURPHARMA 12-Dec-2019 (Continuation news of SQURPHARMA): using the acquisition method when control is transferred to the Company. The consideration transferred in the acquisition is generally measured at fair value, as are the identi?able net assets acquired. As the consideration transferred in the acquisition date is equals to net assets acquired at acquisition date, there is no goodwill or gain on bargain purchase arises as per para-9 of lFRS 3. (end)
SQURPHARMA 12-Dec-2019 (Continuation news of SQURPHARMA): Compensation of shareholders of Square Herbal & Nutraceuticals Ltd. is based on cash at a book value shares as on 30 June, 2017 subject to approval by the Court of Jurisdiction, Hon'ble High Court Division of the Supreme Court of Bangladesh. IFRS Followed for the Business Combination: The Company accounts for business combinations (cont. 7)
SQURPHARMA 12-Dec-2019 (Continuation news of SQURPHARMA): Purchase Consideration: Square Pharmaceuticals Ltd. holds 99.50% of the Paid-up Capital of Square Formulations Ltd. with only 0.50% being held by the minority shareholders. Compensation of the minority shareholders is based on cash at a book value shares as on 30 June, 2017 subject to approval by the Court of Jurisdiction, Hon'ble High Court Division of the Supreme Court of Bangladesh. (cont. 6)